Search PubMedSearch

PubMed · 8159307

Complement activation during CAPD.

Abstract

Complement activation was monitored in 20 CAPD patients and 20 normal individuals using markers of the alternative (Bb fragment), classical (C4d fragment), common (iC3b) and terminal pathways (SC5b-9, the soluble form of the membrane attack complex, MAC), together with C3, C4 and factor B. CAPD plasma SC5b-9 was higher than normal although this was not due to increased complement activation in the plasma. The calculated cleavage for C3, C4 and factor B to iC3b, C4d and Bb respectively, due to spontaneous activation, was similar in both groups. C3, C4 and factor B in dialysate were less than 1% of plasma concentration, consistent with vascular leakage, whereas iC3b, Bb and SC5b-9 were at higher concentrations, suggesting generation in the peritoneum by the alternative pathway. 2.4% C4d is consistent with leakage of this small molecule but may indicate slight classical activation. It is concluded that complement activation occurs in the peritoneum during CAPD. MAC and the anaphylatoxins which are also generated may contribute to an increased risk of infection and other inflammatory complications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G A Young, S Kendall, A M Brownjohn. 1993. Complement activation during CAPD.. https://pubmed.ncbi.nlm.nih.gov/8159307/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Peripheral blood stem cell transplantation. Part 2.

This is the second of a two-part series looking at the increasing use of peripheral blood stem cell transplant as a treatment for certain types of malignancy. Last week's article reviewed the history of the treatment and discussed how the cells are collected. This article discusses the nursing care of patients undergoing transplant and looks at the future implications of the treatment.

Blood

Membrane permeability and stability in buffer and in human serum of fluorinated di-O-alkylglycerophosphocholine-based liposomes.

The stability (with respect to encapsulated carboxyfluorescein release) of liposomes made from various fluorocarbon 1,2-or 1,3-di-O-alkylglycerophosphocholines (ether-connected) and their membrane permeability have been investigated in buffer and in human serum. Membranes and liposomes, whether formulated with fluorocarbon/fluorocarbon or mixed fluorocarbon/hydrocarbon, 1,2- or 1,3-di-O-alkylglycerophospholipids, display lower permeability coefficients and are able to retain more efficiently encapsulated CF, even when incubated in human serum, than any of their conventional counterparts. These fluorinated liposomes are as stable as the first generation of liposomes formulated with their fluorocarbon ester-connected 1,2-di-O-acylglycerophosphocholine analogs. These results further confirm that a fluorinated intramembranar layer reduces the permeability of membranes (more significantly when they are in a fluid state), protects them from the destabilizing effects of serum components and increases even the stability of the fluorinated liposomes whose membranes are in the gel state when incubated in human serum. The impact of the modular structure of the fluorinated phospholipids (number of fluorocarbon chains, ether vs. ester bond, 1,2- vs. 1,3-isomer, etc...) and structure/permeability/ stability relationships are also presented.

Blood

Do physiological concentrations of IgG induce a direct aggregation of red blood cells: comparison with fibrinogen.

Under physiological conditions, red blood cells (RBCs) form aggregates that allow blood flow in all the circulatory system. RBC aggregation is the result of local flow shear stress, erythrocyte properties and macromolecular interactions between adjacent cells. Plasma proteins like fibrinogen or IgG are considered to promote RBC aggregation by a mechanism that remains to be explained. In the present study, we have examined the precise role of IgG on RBC fast-phase aggregation, in comparison with that of fibrinogen. Under our experimental conditions, we observed no fast-phase aggregating effect for IgG, at either physiological or supraphysiological concentrations, while fibrinogen induces strong aggregation of RBC. We also suspect the other plasma proteins to play a role in the RBC aggregating process.

Blood